House Passes ACT for ALS Reauthorization Act with ALS Network Support
The ALS Network applauded the U.S. House of Representatives for passing the ACT for ALS Reauthorization Act, extending critical research and therapy access programs through 2031.
Los Angeles, CA – The ALS Network has expressed its approval following the U.S. House of Representatives' passage of the Accelerating Access to Critical Therapies (ACT) for ALS Reauthorization Act of 2026 (H.R. 8205). This bipartisan legislation, championed by Representatives Ken Calvert and Mike Quigley, aims to extend key ACT for ALS programs until 2031.
With the current law set to expire on September 30, 2026, the House's approval is a significant step toward ensuring the continuation of these vital programs. The ALS Network is now urging the Senate to swiftly advance the legislation to prevent disruptions in ALS research and patient access to ongoing treatments.
The ACT for ALS legislation was established to accelerate research into Amyotrophic Lateral Sclerosis and expand access to investigational therapies for patients unable to participate in traditional clinical trials. These programs are particularly crucial for a disease with limited time and few effective treatment options.
"Today’s passage of the ACT for ALS Reauthorization Act is an important milestone for people living with ALS and their families," stated Sheri Strahl, President and CEO of the ALS Network. She emphasized that the vote brings the community closer to ensuring continued progress in research and treatments and thanked the lawmakers for their support.